Lyra Therapeutics, Inc. (LYRA) has disclosed a new risk, in the Manufacturing category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lyra Therapeutics, Inc. faces significant business risks following the recent restart of manufacturing for LYR-210, primarily due to the transition from a contract manufacturing organization to an in-house facility. The company has yet to establish a commercial manufacturing capability, and ongoing reliance on outsourced services poses challenges, including potential lot failures and regulatory hurdles. Additionally, the reduction in experienced personnel after the May 2024 RIF could lead to production delays, impacting clinical and regulatory timelines. These factors, combined with potential trade disruptions, may hinder Lyra’s attractiveness to potential collaborators and affect its financial stability.
Overall, Wall Street has a Hold consensus rating on LYRA stock based on 5 Holds.
To learn more about Lyra Therapeutics, Inc.’s risk factors, click here.